Ursodeoxycholic acid

Category:Active Pharmaceutical Ingredients > Digestive System Drugs
Product Name:Ursodeoxycholic acid
CAS No.:128-13-2
Standard:ChP, USP, EP
Price(USD):1~10
Company:Arshine Group Co.,Ltd.

Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Block 14, No.100, Luyun Road, Changsha 410205, Hunan, China.

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Payment Terms: L/C

    Discover the therapeutic wonders of Ursodeoxycholic Acid(CAS No.128-13-2) (UDCA), a remarkable medication known for its efficacy in promoting liver health and managing various hepatobiliary conditions. Sourced from natural bile acids, this potent compound has been extensively studied and trusted by healthcare professionals worldwide. Embrace the power of Ursodeoxycholic Acid to support liver function and improve overall well-being.

    What is Ursodeoxycholic Acid?

    Ursodeoxycholic Acid, also known as UDCA or ursodiol, is a secondary bile acid found in small quantities in human bile. However, in medicinal formulations, UDCA is derived from synthetic or bear bile sources. It is renowned for its unique properties that aid in reducing cholesterol levels in bile, protecting liver cells, and assisting in the dissolution of certain gallstones.

    How Does Ursodeoxycholic Acid Work?

    UDCA's mechanism of action revolves around its dual benefits for liver health. Firstly, it helps to promote the flow of bile, reducing cholesterol saturation in the gallbladder, and preventing the formation of cholesterol-based gallstones. Secondly, UDCA exhibits cytoprotective properties, which means it safeguards liver cells from damage, inflammation, and apoptosis, thus supporting overall liver function.

    Key Features and Benefits:

    Gallstone Management: Ursodeoxycholic Acid is effective in dissolving small cholesterol gallstones, reducing the need for surgical interventions and facilitating a safer, non-invasive approach to gallstone management.

    Primary Biliary Cholangitis (PBC): UDCA is the primary treatment for PBC, an autoimmune liver disease. It helps slow disease progression, improve liver function, and enhance patients' quality of life.

    Non-alcoholic Fatty Liver Disease (NAFLD): UDCA shows promise in NAFLD treatment, assisting in reducing liver fat content and inflammation, potentially preventing disease progression.

    Liver Protection: The cytoprotective properties of Ursodeoxycholic Acid make it an essential component in liver protection and regeneration strategies.

    Cholesterol Reduction: UDCA can effectively lower serum cholesterol levels, making it beneficial for individuals with certain cholesterol-related conditions.

    Test item

    Test standard

    Test result

    Appearance

    White    or    almost    white    crystalline powder, taste bitter, without stink

    Complied

    Identification

    Enterprise Standard

    Complied

    Related Substance

    Lithocholic Acid ≤ 0. 1%

    Chenodeoxycholic Acid  1.0%

    Other Max. Individual Impurity ≤ 0.20% Total Impurity 2.0%

    Complied

    Specific Optical Rotation

    +58° - +62°

    +59.3°

    Melting Point

    200℃ -204℃

    201.0℃-202.6℃

    Loss on Drying

    ≤0.5 %

    0. 10%

    Ignition Residue

     0. 10%

    0.07%

    Heavy Mental

     10ppm

    Complied

    Assay (Titration)

    ≥ 99.2%— 101.0%

    100.2%

Send your message to this supplier
  • From:
  • To:
    Arshine Group Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service